Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H1 2018

  • ID: 4518517
  • Report
  • 74 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Denali Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • MORE
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H1 2018

Summary:

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Beta-secretase 1 (BACE1) is an enzyme that in humans is encoded by the BACE1 gene. It is responsible for the proteolytic processing of the amyloid precursor protein (APP). It cleaves at the N-terminus of the A-beta peptide sequence of APP. This leads to the generation and extracellular release of beta-cleaved soluble APP and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase.

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) pipeline Target constitutes close to 25 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes.

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 1, 1 and 12 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Alzheimer's Disease, Dementia Associated With Alzheimer's Disease and Mild Cognitive Impairment.

The latest report Beta Secretase 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)
  • The report reviews Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Denali Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • MORE
Introduction

Report Coverage

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Overview

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Companies Involved in Therapeutics Development

Allgenesis Biotherapeutics Inc

Amgen Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Denali Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Genentech Inc

H. Lundbeck AS

Johnson & Johnson

Novartis AG

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Drug Profiles

AG-12896 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-8718 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVCRI-104P3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Inhibit BACE1 and MAPT for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNP-520 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elenbecestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ER-901356 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNE-892 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-1911 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanabecestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LuAF-66432 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-2811376 + LY-3002813 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3202626 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides to Activate miR-188-3p for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BACE 1 for Alzheimer’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BACE1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BACE1 for Alzheimer’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit APP-Selective BACE Enzyme for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE-1 and GSK-3 Beta for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE1 for Alzheimer Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Dormant Products

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Discontinued Products

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Product Development Milestones

Featured News & Press Releases

Feb 05, 2018: Compound Designed to Fight Alzheimer’s Disease Shows Promise in the Lab

Oct 31, 2017: Eisai To Present Latest Data On Elenbecestat At 10th Clinical Trials On Alzheimer's Disease

Jul 17, 2017: Eisai Presents 3 Posters On Elenbecestat at the 2017 Alzheimers Association International Conference

Mar 29, 2017: Enrollment Commences In Phase III Clinical Study Of Eisai's Bace Inhibitor Elenbecestat In Early Alzheimer's Disease In Japan

Dec 12, 2016: Eisai Presents Latest Data On Bace Inhibitor Elenbecestat (E2609) At 9Th Clinical Trials On Alzheimer’s Disease

Nov 18, 2016: U.S. FDA Grants Fast Track Designation For The Development Of Eisai’s Bace Inhibitor E2609 For Early Alzheimer’S Disease

Oct 31, 2016: Enrollment Commences In Phase III Clinical Study Of Eisai's Bace Inhibitor E2609 In Early Alzheimer's Disease

Aug 22, 2016: Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease

Aug 09, 2016: U.S. FDA Confirms Sufficient Data to Advance Investigational Bace Inhibitor E2609 for Treatment of Early Alzheimer’s Disease to Phase III

Jun 14, 2016: New Alzheimer’s Study Aimed at Preventing or Delaying Symptoms

Apr 08, 2016: AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer’s disease

Dec 01, 2014: AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer’s disease

May 07, 2014: AstraZeneca In Discussions For Partnership To Develop Alzheimer's Drug

Apr 24, 2013: GE Healthcare And Eisai To Partner On Alzheimer's Disease Research

Jul 19, 2012: Eisai Presents First Clinical Data For BACE Inhibitor E2609 At AAIC 2

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Allgenesis Biotherapeutics Inc, H1 2018

Pipeline by Amgen Inc, H1 2018

Pipeline by AstraZeneca Plc, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by Denali Therapeutics Inc, H1 2018

Pipeline by Eisai Co Ltd, H1 2018

Pipeline by Eli Lilly and Co, H1 2018

Pipeline by Genentech Inc, H1 2018

Pipeline by H. Lundbeck AS, H1 2018

Pipeline by Johnson & Johnson, H1 2018

Pipeline by Novartis AG, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allgenesis Biotherapeutics Inc
  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Denali Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Genentech Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • Novartis AG
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll